Enquiring About Tolerance Trial (EAT); Learning Early About Peanut allergy trial (LEAP); skin prick test (SPT)

Follow-up study led by Dr. Gideon Lack, which found that targeting only the highest-risk infants with severe eczema reduced the population disease burden by only 4.6%, whereas when the intervention was targeted to the larger but lower-risk groups, there was a 77% reduction in peanut allergy. The estimated reduction in peanut allergy diminished with every month of delayed introduction.